SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Neurogen (NRGN) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (452)1/1/2007 9:34:43 PM
From: NeuroInvestment  Read Replies (1) | Respond to of 523
 
Tuck:

I hope Anesiva's DD regarding competition is not representative of its overall capabilities. Painceptor does not have a VR1 program (their pain programs have acid-sensing ion channels and NGF receptors as their targets). Purdue did, but I believe they ran into some IP problems (I think with Neurogen) and had to back off. Whether they have a backup program I don't know, but I doubt they are clinic-ready if they do.

FWIW.

Harry
NeuroInvestment



To: tuck who wrote (452)1/24/2007 8:27:20 PM
From: tommysdad  Respond to of 523
 
GSK is in PII:

gsk.com

705498 under Neurosciences.

They probably searched for VR1, as opposed to TRPV1 . . .



To: tuck who wrote (452)3/5/2007 3:37:53 PM
From: tommysdad  Read Replies (1) | Respond to of 523
 
GSK has updated their pipeline, and their TRPV1 molecule is no longer listed as being in the clinic, FWIW. Seems the front-runner hath fallen.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News